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Abstract
Background: Circadian disruption and deranged molecular clockworks are involved in carcinogenesis. The
cryptochrome genes (CRY1 and CRY2) encode circadian proteins important for the functioning of biological oscillators.
Their expression in human colorectal cancer (CRC) and in colon cancer cell lines has not been evaluated so far.
Methods: We investigated CRY1 and CRY2 expression in fifty CRCs and in the CaCo2, HCT116, HT29, SW480 cell lines.
Results: CRY1 (p = 0.01) and CRY2 (p < 0.0001) expression was significantly changed in tumour tissue, as confirmed in a
large independent CRC dataset. In addition, lower CRY1 mRNA levels were observed in patients in the age range of 62-
74 years (p = 0.018), in female patients (p = 0.003) and in cancers located at the transverse colon (p = 0.008). Lower CRY2
levels were also associated with cancer location at the transverse colon (p = 0.007). CRC patients displaying CRY1
(p = 0.042) and CRY2 (p = 0.043) expression levels over the median were hallmarked by a poorer survival rate.
Survey of selected colon cancer cell lines evidenced variable levels of cryptochrome genes expression and time-
dependent changes in their mRNA levels. Moreover, they showed reduced apoptosis, increased proliferation and
different response to 5-fluorouracil and oxaliplatin upon CRY1 and CRY2 ectopic expression. The relationship with
p53 status came out as an additional layer of regulation: higher CRY1 and CRY2 protein levels coincided with a
wild type p53 as in HCT116 cells and this condition only marginally affected the apoptotic and cell proliferation
characteristics of the cells upon CRY ectopic expression. Conversely, lower CRY and CRY2 levels as in HT29 and
SW480 cells coincided with a mutated p53 and a more robust apoptosis and proliferation upon CRY transfection.
Besides, an heterogeneous pattern of ARNTL, WEE and c-MYC expression hallmarked the chosen colon cancer cell
lines and likely influenced their phenotypic changes.
Conclusion: Cryptochrome gene expression is altered in CRC, particularly in elderly subjects, female patients and
cancers located at the transverse colon, affecting overall survival. Altered CRY1 and CRY2 expression patterns and
the interplay with the genetic landscape in colon cancer cells may underlie phenotypic divergence that could
influence disease behavior as well as CRC patients survival and response to chemotherapy.
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Background
Biological phenomena underling physiology and behav-
ior show rhythms with about 24-h (circadian) periodicity
featuring a wide range of cellular and tissue processes as
well as organ functions. Nycthemeral rhythmicity is driven
by the circadian timing system, a hierarchical structure
hard-wired by central and peripheral biological oscillators
[1, 2]. The central oscillators are located in the suprachias-
matic nuclei (SCN) of the anterior hypothalamus, small
regions positioned at each side of the III ventricle and
composed of approximately 20.000 neurons in mice and
100.000 neurons in humans [1, 2]. The SCN respond to
external cues, principally photic information transmitted
through the retino-hypothalamic tract and dictated by the
environmental light-darkness alternation, and drive per-
ipheral oscillators present in nearly all body tissues and
organs via neural pathways (autonomic nervous system)
as well as humoral outputs (melatonin, cortisol) [1, 2].
The biological clocks endowed in central and peripheral
oscillators are operated by molecular clockworks tick-
ing by means of a transcription-translation feedback
loop encompassing a set of circadian genes and proteins
and revolving with a free-running period of about 24 h
[3, 4]. The negative limb of this loop relies on period
(PER 1-3) and cryptochrome (CRY1 and CRY2) genes
activated by heterodimers of the transcription factors
CLOCK and ARNTL (also called BMAL1). PER and CRY
proteins form a repression complex in the cytoplasm,
which translocates into the nucleus and interacts directly
with CLOCK and ARNTL [5]. The casein kinase (CK) Iδ
and CKIε may target them for degradation and regulate
their nuclear translocation [6]. CLOCK and ARNTL also
activate the expression of NR1D1 and Rora genes, en-
coding the nuclear receptors REV-ERBα and RORα, re-
spectively. The rhythmic transcription of ARNTL is also
regulated by these receptors, as REV-ERBα prevents the
binding of the positive transcriptional regulator RORα
to specific response elements in gene promoters [7, 8].
The clock gene machinery controls cell metabolism, prolif-
eration, differentiation, DNA damage response, apoptosis,
and autophagy [9]. In particular, the chryptochrome genes
influence cell cycle progression and lack of Cry proteins in
cultured primary Cry1-/-Cry2-/- mouse fibroblasts is associ-
ated with faster cell proliferation [10]. Disruption of the
circadian clock may lead to deregulated cellular pro-
cesses driving carcinogenesis, in particular in colorectal
tissues and may influence the response to chemothera-
peutic agents [11–13]. Cry1-/-Cry2-/- double knockout
mice are hallmarked by constitutively high resistance to
cyclophosphamide, and show a constant active state of
CLOCK:BMAL1 heterodimers, inducing high level ex-
pression of target genes at any time of the circadian
cycle [14]. Besides, CLOCK gene amplification and overex-
pression was associated with a high risk for colorectal
cancer (CRC) and with poor prognosis in CRC patients.
Experiments performed in vitro showed that CLOCK
up-regulation propped up proliferation and restrained
apoptosis in SW480 cells, whereas CLOCK down-
regulation slowed down proliferation and speeded up
apoptosis in SW620 cell. At the molecular level, CLOCK
over-expression induced significant reduction of Bax and
Bid expression as well as significant increase in p‑AKT ex-
pression, while CLOCK silencing induced significant dim-
inution in p‑AKT expression without influencing total
AKT levels [15].
CRC is the third most common type of human cancer
in both sexes and the second most common cause of can-
cer death in Western countries [16, 17]. Surgical interven-
tion in early stages represents the only effective treatment,
whereas chemotherapy has modest effects, suggesting the
need for new prognostic molecular biomarkers and thera-
peutic approaches.
Advances in molecular chronobiology have led to the
development of cancer chronotherapy, which refers to
the use of rhythmic cycles in the application of therapy.
Following a time qualified treatment schedule, the intent
is to promote both the anti-cancer action of drugs, and
limit the drug-related side effects [18]. On the premise
that circadian clocks control cellular proliferation and
drug metabolism over the 24 h, previously untreated
CRC patients bearing unresectable liver metastases were
treated with chronomodulated chemotherapy regimen
with 5-fluorouracil (5FU), leucovorin, and oxaliplatin
(OXA), called chronoFLO4 [19]. Unfortunately, this lat-
ter approach offered no survival advantage as compared
to conventional chemotherapy, and differences in toxicity
and outcome between male and female patients were
apparent [20]. Indeed, chemotherapeutic agents attenu-
ate the oscillating expression of circadian genes, caus-
ing chronodisruption, particularly in female patients,
attributable to gender related differences in circadian
cycle [21]. The search for reliable and valuable circadian
biomarkers for non invasive monitoring is necessary to
define the optimal circadian timing of chemotherapy [22].
Sex dimorphism in mice and humans impinges on
hepatic drug metabolism [23], and dimorphic liver me-
tabolism is altered when the cryptochrome genes are
inactivated. The levels of sex-specific liver products, in-
cluding several cytochrome P450 enzymes, expressed by
Cry1-/-Cry2-/- male mice are similar to those expressed
by female mice. Besides, an altered pattern of circulating
growth hormone (GH) has been evidenced in Cry1-/-
Cry2-/- male mice, suggesting a 24-h clock control and
pacing on the dimorphic ultradian pulsatility of GH,
which is responsible for sex-dependent liver activity [24].
Uncovering the relationships among circadian timing,
sex dimorphism and liver metabolism would be crucial
to customize chronotherapy. The aim of our study was
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to evaluate the expression patterns of CRY1 and CRY2 in
neoplastic tissues of male and female CRC patients and
in colon cancer cell lines in order to validate preliminary
results previously obtained by our group [25] and ex-
plore the role of cryptochrome genes in colon cancer
cell behaviour and response to chemotherapeutic agents.
Methods
Sample size
We had to enroll at least 45 patients in order to achieve
a power of 80 % with a type I error of 5 % in detecting a
gene expression difference of 0.30 between the CRC
tumour tissue and normal mucosa, using a two-sided
two-sample t-test and analysis of variance (ANOVA)
(standard deviation of 0.50. A total number of 30 subjects
was required for Pearson’s correlation with a correlation
coefficient of 0.50 and a type I error of 5 %.
Patients
This study was approved by the Ethical Board of our In-
stitute, and all patients gave written informed consent.
The experimental protocol conformed to international
ethical standards. CRY1 and CRY2 mRNA and protein
levels were evaluated in the tumour tissues and adjacent
normal tissues of 50 patients (34 men and 16 women,
mean age ± SD 67.2 ± 11.6 years) undergoing surgery for
primary colorectal cancer at our Hospital. Patient char-
acteristics are shown in Table 1. All tumoral and normal
tissue specimens were collected between 9:00 a.m. and
17:00 p.m. of the same day (8 h), dissected immediately,
stained with haematoxylin-eosin and analyzed by the
pathologist to determine the tumour cell percentage. Tis-
sue samples having at least 80 % of tumour cell content
were frozen in liquid nitrogen until the molecular analysis.
RNA extraction from fresh frozen tissue and first-strand
cDNA synthesis
Total RNA was extracted with TRIzol reagent (Invitrogen)
from about 150–200 mg of freshly frozen tissue speci-
mens. The amount of total RNA was determined by UV
spectrophotometry using the Nano Drop Spectrophotom-
eter (Nanodrop Technology), and RNA integrity assessed
by the Agilent 2100 Bioanalyzer (Agilent Technologies)
after digestion by DNaseI. Next, 1.0 μg of total RNA was
reversed transcribed using the High-Capacity cDNA
Archive Kit following the manufacturer’s instructions
(Applied Biosystems).
Quantitative real-time reverse transcription-PCR assay
To assess the differential expression of the cryptochrome
genes in CRC specimens and matched normal mucosa,
quantitative real-time PCR (q-PCR) assay was performed
by using CRY1 (QT00025067), CRY2 (QT00094920),
ARNTL (QT00011844), WEE (QT00038199) and c-MYC
Table 1 Clinical and pathological features of colorectal cancer
patients
n = 50 %
Age (years):





Proximal colona 17 34
Transverse colon 6 12
Distal colonb 27 54
Histologic Type
Non-mucinous adenocarcinoma 45 90
Mucinous adenocarcinoma 5 10






























aCaecum and ascending colon
bDescending colon, sigmoid colon and rectum
Mazzoccoli et al. Molecular Cancer  (2016) 15:6 Page 3 of 20
(QT00035406) Human QuantiTec Primers Assay (SYBR
Green QuantiTect Primers Assay; QIAGEN). All qPCRs
were performed in a 25-μl final volume, with three repli-
cates per sample, by using QuantiFast SYBR Green PCR
kit (QIAGEN) and run in an ABI PRISM® 7700 Sequence
Detection System (Applied Biosystems). The data were
analyzed using the default and variable parameters avail-
able in the SDS software package (version 1.9.1; Applied
Biosystems). GAPDH housekeeping control gene was used
to normalize target gene expression levels and the mRNA
amount of each target gene relative to GAPDH was calcu-
lated through the comparative Ct method, also called the
2(−ΔΔCt) method. Two biological replicates were each
assayed in triplicate and results were expressed as mean ±
standard deviation (SD).
Microsatellite instability
The Microsatellite instability (MSI) analysis was performed
using the Bethesda panel of microsatellite (BAT25, BAT26,
D5S346, D17S250 and D2S123) evaluated by means of a
multiplex-PCR and PAGE analysis. Tumours showing in-
stability in four or more markers were classified as high
MSI (MSI-H), those showing instability in two markers as
low MSI (MSI-L), and those showing no instability as
microsatellite-stable (MSS).
Cell culture
CaCo2, HCT116, HT 29 and SW480 colon cancer cell
lines were acquired from ATCC (American Type Cell
Culture) and cultured as appropriate at 37 °C in 5 %
CO2 atmosphere in Dulbecco’s modified Eagle’s medium
(DMEM) and Minimum Essential Medium (MEM) Alpha
media, supplemented with 10 % fetal bovine serum (FBS),
100 U/ml penicillin and 100 ng/ml streptomycin (Invitrogen
Life Technologies). For experiments utilizing synchronized
cells and not synchronized cells, CaCo2, HCT116, HT 29
and SW480 cells were seeded at 5 × 105cells/well in 6-well
plates. For synchronized cells serum shock was used as
synchronization procedure [26]. Briefly, the day of the exper-
iments culture medium was exchanged with serum-rich
medium with 50 % FBS only for synchronized cells and after
2 h this medium was replaced with 10 % FBS. The cells were
harvested every 3 h over 60 h for CRY1 and CRY2 evalu-
ation and every 4 h over 28 h for ARNTL, c-MYC and WEE
evaluation. Two biological replicates were each assayed in
triplicate and results were expressed as mean ± standard
deviation (SD).
Immunoblot analysis
Tissues and cells were lysed in RIPA buffer (150 mM
NaCl, 50 mM Tris-HCl, pH 8, 1 % NP40, 0.1 % SDS,
0.5 % sodium deoxycholate) supplemented with Protease
Inhibitor Cocktail Tablets (ROCHE). After centrifugation
at 13.000 rpm for 10 min at 4 °C, the supernatants were
collected as whole cell protein samples. After boiling at
95 °C for 5 min, an equal amount of proteins was loaded
on 10 % polyacrylamide gels and separated by electro-
phoresis. Protein transfer was performed on PVDF
membrane (VWR). Membranes were blocked with 5 %
nonfat milk in wash buffer (0.2 M Tris-HCl, pH 7.6,
1.5 M NaCl, 0.1 % Tween 20) and incubated with the
specific primary antibodies diluted in blocking solution,
at the appropriate dilutions. Following three washes,
membranes were incubated at room temperature for 1 h
with a secondary anti-rabbit or anti-mouse antibody diluted
in blocking solution. After three further washes, proteins
were revealed by chemiluminescence (ECL, Amersham
Biosciences AB) and the signal detected on an X-ray film
(Amersham Biosciences AB). We used the following anti-
bodies: affinity purified rabbit anti-CRY1 antibody (Bethyl
Laboratories, INC) diluted 1:1000; affinity purified rabbit
anti-CRY2 antibody (Bethyl Laboratories, INC) diluted
1:1000; anti-p53-DO7 antibody (Novacastra) diluted
1:500; anti-β-Actin (C4) from Santa Cruz (DBA) diluted
1:5000; rabbit anti-FLAG antibody (Sigma-Aldrich) di-
luted 1 μg/ml; anti-β-Actin (C4) from Santa Cruz (DBA)
diluted 1:5000; anti-rabbit or anti-mouse IgG, HRP-linked
secondary antibody from Cell Signaling (Euroclone) di-
luted 1:2000. Each western blot analysis was performed
five times.
Fluorescent in situ hybridization
The colon cancer cell lines used in the study were tested
by Fluorescent In Situ Hybridization (FISH) to detect
copy number alterations of the cytobands harboring the
CRY1 (12q23.3) and CRY2 genes (11p11.2). BAC (Bacterial
Artificial Chromosomes) clones encompassing the two
genes were selected according to the February 2009
release (GRCh37/hg19) of the University of California
at Santa Cruz (UCSC) Human Genome Browser
(http://genome.ucsc.edu). We used RP11-632 M14
(chr12:107,260,199-107,462,448) and RP11-1084E2 (chr11:
45,808,132-45,997,341) for CRY1 and CRY2, respectively
(Fig. 4). Metaphase spreads were prepared as described
elsewhere [27]. FISH experiments and digital images acqui-
sition were carried out as previously described [28].
Cell transfection
CaCo2, HCT116, HT-29 and SW480 cell lines at 70-80 %
confluence were transiently transfected with PFMH-
hCry1 or pSO2002 plasmids carrying the full length
cDNA for CRY1 and CRY2, respectively, fused in frame at
their 5’ end to a DNA segment coding for the FLAG epi-
tope (Plasmid #25843, and Plasmid #25842, respectively;
Addgene) or with the empty control plasmid pcDNA™4/
myc-His (Plasmid # V863-20; Invitrogen) by using Lipo-
fectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. After 6 h of incubation at 37 °C, the
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transfection medium was replaced with complete medium
containing 10 % FBS and the experiments were conducted
72 h later.
Cell proliferation assay with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) and evaluation of
response to chemotherapeutic agents upon CRY1 and
CRY2 ectopic transfection
The cells were seeded onto a 96-well plates in 200 μL
medium, at a density of 4 × 104 cells/well, and trans-
fected with CRY1 or CRY2 expression vectors. At differ-
ent time points (24, 48, 72 and 96 h) the MTT solution
(5 mg/mL, 20 μL) was added and the plates were incu-
bated for 4 h. The medium was removed and Isopropyl
alcohol (200 μL) added to dissolve the formazan crystals.
The reduction in cell viability was determined colorimet-
rically by using a spectrophotometer at λ = 570 nm and
630 nm. The results are expressed as the mean of optical
density (OD) from triplicate samples. Three independent
experiments were carried out and the results expressed
based on the following formula: cell viability (%) = num-
ber of cells in transfected group/ number of cells in con-
trol group x 100.
CAsy cell counter
Cell number and density of viable cells were determined
using CAsy Cell Counter (Innovatis, Sittingbourne, UK).
Each sample (cell suspension) was prepared three times
in CAsyTon (Innovatis) buffer, followed by triplicate
measurements of 200 μl sample volume. Viable cells
were measured by Casy Cell Counter, by excluding all
counts that were of a size smaller that 10 μm (dead cells
and debris).
Pharmacological treatments
CaCo2, HCT116, HT29 and SW480 cells were treated
for 72 h with the indicated chemotherapeutic agents (10
uM 5FU and 10 uM OXA); alternatively, each cell line
was treated 48 h after transfection with 1 μM, 5 μM,
and 10 μM of 5FU (50 mg/ml concentrate, Sigma-
Aldrich) or OXA (5 mg/ml concentrate, Sigma-Aldrich)
and incubated for 48 h at 37 °C; three biological repli-
cates were each assayed in triplicate and results were
expressed as mean ± standard deviation (SD).
Apoptosis assay by flow cytometry
Apoptosis was evaluated by AnnexinV-FITC and Propi-
dium Iodide stained cells using Apoptosis Detection Kit
(BD Biosciences), according to the manufacturer’s pro-
tocols. All flow cytometry results were analyzed with
FACSuite Software v.1.0.5.3841 (BD Biosciences). Three
biological replicates were prepared and each assayed in
triplicate and the results expressed as mean ± standard
deviation (SD).
Cell-cycle analysis
Cell cycle analysis was performed three days after trans-
fection on both attached and floating cells using the BD
Cycletest Plus DNA reagent Kit (Cat. No. 340242; BD
Biosciences). Propidium Iodide stained cells (>20.000
events) were analyzed by flow cytometry on FACSVerse
(BD Biosciences). Debris and doublet cells were excluded
and only single cells were considered for cell cycle analysis.
Results were reported as percentage of cells in G1, S and
G2/M phases. All flow cytometry results were analyzed
with the FACSuite Software v.1.0.5.3841 (BD Biosciences).
Four biological replicates were prepared and each assayed
in triplicate; the results were reported as mean ± standard
deviation (SD).
Independent dataset analysis
The independent publicly available TCGA COAD series
(https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) was an-
alyzed to examine CRY1 and CRY2 expression in CRC
tissues in comparison to normal mucosa. Normalized
Level 3 data were used for our analysis. (Additional file 1:
Figure S1)
Statistical analysis
CRY1 and CRY2 expression levels in CRC tissue were
compared with those of the adjacent non-tumorous mu-
cosa, calculated using the formula 2-ΔΔCt values and re-
ported as median, 25th percentile (or first quartile, Q1)
and 75th percentile (or third quartile, Q3). Where appro-
priate data of gene expression were log transformed to
achieve normal distribution, verified by Normality test
and Equal variance test. Hypotheses regarding differ-
ences among the values were compared by means of the
paired t-test, Wilcoxon signed rank sum test, Student’s t
test, Mann Whitney rank sum test. Pearson correlation
coefficient r between gene expression levels was evaluated.
Associations between gene expression level and pheno-
typic characteristics were evaluated by using the Pearson’s
chi-squared test. Survival rates were calculated by the
Kaplan–Meier method for analysis of censored data. Sub-
group analyses were performed after splitting subjects at
the median of gene expression levels or sorting them into
quartile groups. For chronobiological analysis, after evalu-
ation by Normality test and Equal variance test, time-
effect across the time points and differences among the
four cell lines at each time point were evaluated by
ANOVA followed by all pairwise multiple comparison
procedures (Student-Newman-Keuls Method). Each time-
series of mRNA expression levels was analyzed for cir-
cadian rhythm characteristics by the single cosinor pro-
cedure involving the fit of a 24 h cosine curve to the
data by least-squares linear regression, in order to ac-
curately describe waveforms and rhythm characteristics.
A p value for the rejection of the zero-amplitude
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assumption was determined for each component in the
cosine model, with rhythm detection considered statis-
tically significant if p < 0.05. Circadian characteristics
were summarized from the 24 h cosine. Rhythm charac-
teristics determined from the best-fitting cosine model in-
cluded the MESOR (the middle of the cosine representing
an adjusted average if unequal time interval), the ampli-
tude, A (half the distance from the peak and trough of the
best fitting curve), and the phase (Ø) of the cosine model
(referenced to an external event, such as the serum shock),
with the peak of a single component cosine called the
acrophase, aØ (acro = peak). A p value <0.05 was consid-
ered statistically significant. All analyses were performed
using the SPSS v17 Statistical Package (SPSS, Chicago, IL,
USA) and the MATLAB statistical package (MathWorks,
Natick, MA, USA).
Results
CRY1 and CRY2 mRNA levels are altered in colorectal
cancer specimens
CRY1 and CRY2 mRNA levels were assessed in 50 pairs
of tumour tissue/non-tumorous mucosa comprising 46
well-moderately differentiated (G1-G2) and 4 poorly
differentiated-undifferentiated (G3-G4) CRCs. Median
values, 25th and 75th percentile of GAPDH-Ct value/
target gene-Ct value are shown in Fig. 1a. CRY1 (median =
0.73, Q1-Q3 = 0.43-1.24, p < 0.01) and CRY2 (median =
0.50, Q1-Q3 = 0.25-0.77, p < 0.001) mRNA levels showed a
statistically significant decrease in tumour tissues in com-
parison to matched non-tumorous tissues (Fig. 1a). These
results were validated by analyzing an independent publicly
available cohort comprising 461 CRC patients (The Cancer
Genome Atlas (TGCA) (https://tcga-data.nci.nih.gov/tcga/
tcgaHome2.jsp) (Colon adenocarcinoma data, COAD)
(Additional file 1: Figure S1). CRY1 and CRY2 mRNA ex-
pression correlated with each other in a Pearson’s correl-
ation test (r =0.607, p < 0.0001) (Fig. 1b). Consistently,
CRY1 and CRY2 protein levels decreased in tumour tissues
compared to the non-tumorous counterpart in a panel of
matched specimens (Fig. 1c).
Association of CRY1 and CRY2 mRNA levels with patients
and tumour characteristics
Genotype-phenotype associations were evaluated in our
CRC patients cohort. After splitting subjects at the me-
dian value of gene expression levels, the decrease of
CRY1 mRNA levels observed in CRC tissue strongly as-
sociated with age, since the lowest expression levels were
detected in patients with age range 62-74 years (p = 0.018),
and with cancer location in the transverse colon (p =
0.008). Moreover, sorting subjects in quartile groups an
association was found with gender, with the lowest levels
detected in female patients (p = 0.003). No significant
association was found between CRY1 mRNA levels and
grading (p = 0.778), modified Dukes stage (p = 0.929),
histological type (p = 0.311) and MSI status (p = 0.659),
(Table 2)
Likewise, lower CRY2 mRNA levels observed in CRC
tissues strongly associated with cancer location, with the
lowest levels detected in the transverse colon (p = 0.007).
No significant association was found between CRY2
mRNA levels and age (p = 0.408), gender (p = 0.677),
grading (p = 0.925), modified Dukes stage (p = 0.397),
histological type (p = 0.083), and MSI status (p = 0.555)
(Table 2).
After stratifying patients according to the median
value of gene expression, subjects with CRY1 (p = 0.042)
and CRY2 (p = 0.043) tumour mRNA levels above the
median showed poorer survival rates in a Kaplan–Meier
analysis of censored data (Fig. 1d). Sorting subjects in
quartile groups the events were represented by one fe-
male subject out of 13 patients in the first quartile, one
female subject out of 24 subjects in the second quartile
and 5 male subjects out of 13 patients in the third
quartile.
Evaluation of CRY1 and CRY2 mRNA and protein levels in
colon cancer cell lines
The time related variation of cryptochrome gene expres-
sion was evaluated at 3-h intervals for sixty hours in four
colon cancer cell lines with and without synchronization
by serum shock. As shown in Figs. 2 and 3, we observed
a time effect for the mRNA expression levels of CRY1
and CRY2 in CaCo2, HCT116, HT29 and SW480 cells,
although circadian rhythmicity of transcription oscilla-
tion was evidenced only in HCT 116 cells. A significant
difference was evidenced for CRY1 and CRY2 mRNA ex-
pression levels among the studied colon cancer cell lines
at the examined time points when compared to non-
tumorous mucosa; considering the harvesting time point
at 21 h after synchronization, the highest CRY1 expres-
sion levels were observed in CaCo2 and HCT116 cells
respect to HT29 cells and especially to SW480 cells; the
highest CRY2 expression levels were observed in CaCo2
cells respect to HT29 and HCT116 cells and especially to
SW480 cells (Additional file 2: Figure S2 and Additional
file 3: Figure S3 and Table 3). Besides, the HCT116 cell
line was hallmarked by higher ARNTL mRNA expression
levels respect to CaCo2, HT29 and SW480 cells; HCT116
and HT29 cells showed the highest c-MYC mRNA expres-
sion levels and HT29 cells showed the highest WEE
mRNA expression levels (Additional file 4: Figure S4 and
Table 3).
Western blot analysis performed on extracts of cells
harvested 22 h after synchronization showed higher
levels of CRY1 and CRY2 proteins in HCT116 cells
compared to the other cell lines examined (Fig. 4a). All
four cell lines were then transiently transfected with
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expression vectors carrying CRY1 and CRY2 cDNAs
fused to the FLAG epitope at their 5’ end and the result-
ing proteins assessed by western blot. The exogenous
proteins, detected by a FLAG specific antibody, exhib-
ited variable levels likely due to a different transfection
efficiency; they were higher in HCT116 than SW480 and
HT29 than Caco2 cells as shown in the relative histo-
gram (p < 0.05) (Fig. 4b and c). Higher p53 protein levels
were found in HT29 and SW480 cells respect to
HCT116, whereas it was not detectable in CaCo2 cells
(Fig. 4d). Protein levels of p53 increased in HCT116 cells
upon CRY1 and CRY2 ectopic expression (p < 0.05 and
p < 0.01), while decreased in HT29 cells upon CRY2 ec-
topic expression (p < 0.05) (Fig. 4e).
FISH comparative analysis of CRY1 and CRY2 copy
numbers in colon cancer cell lines
The occurrence of copy number variations involving
CRY1 and CRY2 genes was assessed by Fluorescence In
Situ Hybridization (FISH) on the studied CRC cell lines
employing specific probes of chromosome 12 and 11
where CRY1 and CRY2 genes are respectively located.
The CRY1 gene displayed a low copy number gain (>2
spots/probe) in HT29 and CaCo2 cells, both having a
Fig. 1 Expression of CRY1 and CRY2 mRNA and protein levels in colorectal cancer tissue and survival rates. a CRY1 and CRY2 mRNA levels analysed by
qRT-PCR in colorectal cancer tissue and compared with matched normal tissue, with GAPDH expression used as the calibrator. A box and whisker plot
is shown representing the interquartile range (IQR) with median, 25th and 75th percentile, minimum and maximum values, as well as outliers indicated
by dots. b x-y plot showing regression lines with 95 % confidence limits between CRY1 and CRY2 mRNA expression levels in tumour tissues of
CRC patients (n = 50, r = 0.607, p < 0.0001) c) CRY1 and CRY2 protein level evaluated by western blotting in a panel of matched specimens of
tumour tissue and non-tumorous tissue. A box and whisker plot is shown representing the interquartile range (IQR) with median, 25th and
75th percentile, minimum and maximum values; d) Cumulative survival of CRC patients according to CRY1 (left) and CRY2 (right) expression
levels. A significant difference was found in cumulative survival rates of CRC patients splitted at the median value according to CRY1 expression (p = 0.042)
and CRY2 expression (p = 0.043). Patients with high expression levels showed significantly poorer survival rates
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whole-chromosome 12 trisomy (Fig. 5e); a marker
chromosome carrying the CRY1 signal was also de-
tected in CaCo2 cells (Fig. 5 f ). Conversely, CRY1 dis-
played two spots in HCT116 and SW480 cells, one of
which was on a normal chromosome 12, while the sec-
ond on a translocated one (Fig. 5c and d). Similarly,
CRY2 disclosed a low copy number gain in SW480 and
HT29 cells, represented by a chromosome 11 trisomy
and tetrasomy, respectively (Fig. 5d and e); in CaCo2
cells an additional signal on a translocated chromosome
11 was detected (Fig. 5 f and e). Conversely, in HCT116
cells, CRY2 displayed only the two normal chromo-
somes 11 signals (Fig. 5c).
Comparative analysis of apoptosis, proliferation, cell cycle
upon cryptochrome genes ectopic expression in colon
cancer cell lines
Data from our tumour specimens led us to hypothesize
that variations in cryptochrome genes expression might
control the transformed cell phenotype. To verify this,
we sought to test the effects on apoptosis and cell prolif-
eration of ectopic CRY1 and CRY2 proteins in CRC cells
(see Figs. 6a and b and 7a and b). Exogenous expression
of both proteins in the HT29 and SW480 cell lines induced
a statistically significant reduction of apoptotic and pre-
apoptotic cells by flow cytometry. Specifically, the induction
was stronger with CRY1 than CRY2 although the
Table 2 Association of Cry1 and Cry2 mRNA levels with clinical and pathological features of colorectal cancer patients
Cry1 Cry2
n = 50 Median Q1 Q3 P value Median Q1 Q3 P value
Age <62 16 1.067 0.727 1.315 0.018 0.661 0.318 0.920 0.408
62-74 19 0.552 0.291 1.078 0.423 0.248 0.770
>74 15 0.715 0.329 0.943 0.434 0.211 0.742
Gender Male 34 0.879 0.427 1.398 0.003 0.432 0.236 0.801 0.677
Female 16 0.686 0.442 0.819 0.551 0.297 0.673
Tumor Location Proximal colona 17 0.722 0.323 1.078 0.008 0.434 0.254 0.742 0.007
Transverse colon 6 0.546 0.389 0.649 0.232 0.127 0.309
Distal colonb 27 0.935 0.560 1.398 0.644 0.280 0.898
Grading G1/G2 45 0.726 0.427 1.174 0.778 0.477 0.248 0.801 0.925
G3/G4 5 0.841 0.556 1.270 0.552 0.309 0.675
Modified Dukes Staging System A 4 0.612 0.419 0.912 0.929 0.326 0.203 0.831 0.397
B 20 0.770 0.562 1.006 0.429 0.202 0.734
C 24 0.713 0.375 1.354 0.572 0.275 0.891
D 2 1.145 0.389 1.901 1.566 0.309 2.823
Histologic Type Non mucinous adenocarcinoma 45 0.318 0.291 0.552 0.311 0.592 0.270 0.607 0.083
Mucinous adenocarcinoma 5 0.798 0.509 1.236 0.477 0.254 0.770
MSI frequency missing 12 - - - 0.659 - - - 0.555
High 9 0,560 0,389 1,174 0,550 0,350 0,717
Low 10 0,770 0,583 1,110 0,403 0,248 0,675
Stable 19 0,628 0,318 1,078 0,592 0,270 1,043
Tumor extent 2 4 0.612 0.419 0.912 0.582 0.326 0.203 0.831 0.625
3 43 0.798 0.495 1.270 0.550 0.267 0.801
4 3 0.389 0.208 1.310 0.309 0.127 0.717
Lymph node involvement N0 24 0.727 0.502 1.006 0.205 0.438 0.230 0.785 0.482
N1 14 0.569 0.318 1.270 0.419 0.269 0.715
N2 12 1.059 0.556 2.020 0.571 0.329 1.135
TNM Stage I-II 27 0.628 0.323 1.398 0.899 0.552 0.270 1.039 0.247
III-IV 23 0.727 0.509 1.078 0.434 0.211 0.770
Vascular Invasion Not 27 0.727 0.509 1.110 0.620 0.552 0.267 0.801 0.621
Yes 23 0.726 0.389 1.580 0.350 0.248 0.717
aCaecum and ascending colon bDescending colon, sigmoid colon and rectum
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transfection efficiency was lower for the former pro-
tein, suggesting a robust effect on apoptosis. Milder
effects were detected in CaCo2 cells for both proteins,
while no variations were detected in HCT116 cells, al-
beit the large amount of the transfected FLAG-tagged
proteins (Fig. 4a and b). In addition, we evaluated cell
proliferation at different time points from transfection
and found that HT29 and SW480 cells in particular,
exhibited a higher proliferation rate than CaCo2 and
HCT116 cells (Fig. 7a and b). Concordant results were
obtained with two independent methods such as auto-
matic cell counting and MTT assay. When the cell
cycle effects were monitored by flow cytometry, ex-
ogenous CRY2 induced an increase of the S phase in
all cell lines with a concomitant reduction of the G1
phase cell population; in contrast, CRY1 produced a
less evident effect (Fig. 7c).
Data from the literature have reported that the TP53
status influences CRY1 and CRY2 response in vivo. We
assessed basal levels of p53 in the four cell lines investi-
gated and the effects of exogenous CRY1 and CRY2 on
p53 protein levels. Upon CRY expression constructs
transfection, SW480 and HT29 cells, which exhibit high
levels of a mutated p53 protein (R273H), displayed only
a slight reduction. CACO2 cells showed no p53 protein
due to a truncating mutation (G204X), while HCT116
cells exhibited an increase of the wild type p53 protein
(Fig. 4e).
Evaluation of response to chemotherapeutic agents upon
cryptochrome genes ectopic expression in colon cancer
cell lines
Having shown that cryptochrome genes expression af-
fects cell death and proliferation, we sought to verify
whether they might influence the response to chemother-
apeutic agents in colon cancer cells. To this aim, we evalu-
ated changes in apoptosis/cell viability upon exposure to
selected drugs in basal conditions and after ectopic cryp-
tochrome gene expression.
A variable response to 10 uM 5FU and 10 uM OXA
was detected in all four cell lines, with Caco2 cells being
the most responsive ones (Fig. 8a).
Fig. 2 Time related patterns of cryptochrome gene expression in colon cancer cell lines. Relative expression of CRY1 mRNA level in CaCo2,
HCT116, HT29 and SW480 cells with and withour synchronization with serum shock (SS). Two biological replicates were each assayed in triplicate
and results were expressed as mean ± standard deviation (SD)
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CRY1 ectopic expression in CaCo2 cells did not influence
the cytopathic effect upon treatment with 5FU while
increased that of 1 μM OXA (p < 0.05); CRY2 ectopic
expression increased the cytopathic effect upon treat-
ment with 10 μM 5FU (p < 0.05) and 5 μM and 10 μM
OXA (p < 0.05). In HCT116 CRY1 ectopic expression
decreased the cytopathic effect upon treatment with 1,
5 and 10 μM 5FU (p < 0.05) and increased that of 1, 5
and 10 μM OXA (p < 0.05 and p < 0.01 respectively).
On the other hand, CRY2 ectopic expression decreased
the cytopathic effect upon treatment with 1, 5 and 10 μM
5FU (p < 0.05) and did not influence the effect of OXA. In
HT29 cells CRY1 ectopic expression increased the cyto-
pathic effect upon treatment with 1 μM and 5 μM 5FU
(p < 0.05) and 10 μM OXA (p < 0.05), whereas CRY2 ec-
topic expression increased the cytopathic effect upon
treatment with 1 μM 5FU (p < 0.05) and 10 μM OXA
(p < 0.05). In SW480 cells CRY1 and CRY2 ectopic expres-
sion decreased the cytopathic effect upon treatment with
5FU (p < 0.05) and increased the cytopathic effect upon
treatment with 1 μM OXA (p < 0.05) (Fig. 8b).
Discussion
In the present study, we evaluated the expression of
cryptochrome genes in tumour tissues of a large cohort
of CRC patients and explored their expression patterns
in synchronized colon cancer cell lines. CRY1 and CRY2
mRNA levels were significantly changed in CRC tissue
when compared to matched non-tumorous mucosa, and
there was a positive linear correlation between mRNA
expression levels of both cryptochrome genes, probably
indicating a corresponding and parallel alteration in
tumour tissues. These data broaden the results obtained
in a previous study [25] and were validated by an inde-
pendent publicly available dataset (461 CRC patients of
The Cancer Genome Atlas (TGCA) cohort). Moreover,
the observed CRY1 mRNA levels strongly correlated with
age, being the lowest levels detected in the group of pa-
tients 62–74 years of age. Epidemiological data report
higher incidence of CRC in the elderly, with 80-90 % of
cases arising in people who are in the sixties or older and
the median age at presentation is 72 years. Up to 50 years
of age, men and women exibit similar rates for bowel
Fig. 3 Time related patterns of cryptochrome gene expression in colon cancer cell lines. Relative expression of CRY2 mRNA level in CaCo2,
HCT116, HT29 and SW480 cells with and withour synchronization with serum shock (SS). Two biological replicates were each assayed in triplicate
and results were expressed as mean ± standard deviation (SD)
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cancer, but at older ages male rate predominates, and
the lifetime risk of being diagnosed with CRC is re-
ported to be 5.9 % for men and 5.5 % for women [16, 17].
Additionally, lower CRY1 mRNA levels were found in fe-
male CRC patients, while higher CRY1 and CRY2 levels
were observed in tumours located at the distal colonic
segments (descending and sigmoid colon, rectum). In con-
trast, lower CRY1 and CRY2 expression was found in
tumour tissues located at the transverse colon. Epidemio-
logical data report that 70 % of new CRCs occurs in the
colon (25 % in the sigmoid colon), while the remaining
30 % arises in the rectum; the transverse colon is a rela-
tively less frequent tumour location, although more fre-
quent in female patients [16, 17]. These data support our
present evidence of an association between female gender,
tumour location at the transverse colon and lower expres-
sion of cryptochrome genes. In mammals, xenobiotic de-
toxification is a clock controlled function, with hepatic,
intestinal and renal detoxification systems showing circa-
dian variations of their ability to inactivate noxious agents,
determining time-dependent activity and toxicity of drug
administration [29]. Chronomodulated chemotherapy has
shown better tolerability and antitumour activity with re-
spect to conventional chemotherapy, with less mielosup-
pression in spite of more gastrointestinal toxicity, but no
difference in median survival time. A gender related differ-
ence was observed, with a median survival with chrono-
therapy approximately 5 months longer in male CRC
patients and greater incidence of severe toxicities in fe-
male CRC patients [30].
Table 3 Summary of experimental data for the colon cancer cell lines examined
CaCo2 HCT116 HT29 SW480
CRY1 endogenous mRNA levela ↑↑↑ ↑↑ ↑↑ ↑
CRY2 endogenous mRNA levela ↑↑↑ ↑↑ ↑↑ ↑
CRY1 endogenous protein levelb ↑ ↑↑↑ ↑ ↑↑
CRY2 endogenous protein levelb ↑↑ ↑↑↑ ↑ ↑
CRY1 ectopic protein level ↑ ↑↑↑ ↑ ↑
CRY2 ectopic protein level ↑ ↑↑↑ ↑ ↑
TP53 status mutated (Ø) wild-type mutated (GOF) mutated (GOF)
p53 endogenous protein level Ø ↑ ↑↑↑ ↑↑↑
p53 endogenous protein level upon CRY1 ectopic expression Ø ↑↑ = =
p53 endogenous protein level upon CRY2 ectopic expression Ø ↑↑ ↓ =
ARNTL endogenous mRNA levela ↑ ↑↑↑ ↑ ↑
c-MYC endogenous mRNA levela ↑ ↑↑↑ ↑↑↑ ↑
WEE endogenous mRNA levela ↑ ↑↑ ↑↑↑ ↑↑
Cell pre-apoptosis upon CRY1 ectopic expression = = ↓↓ ↓↓
Cell pre-apoptosis upon CRY2 ectopic expression ↓ = ↓ ↓↓
Cell apoptosis upon CRY1 ectopic expression = = ↓↓ ↓↓
Cell apoptosis upon CRY2 ectopic expression ↓ = ↓ ↓↓
Cell viability upon CRY1 ectopic expression = ↑↑ ↑↑ ↑↑
Cell viability upon CRY2 ectopic expression ↑ ↑↑ ↑↑ ↑↑
Cell cycle changes upon CRY1 ectopic expression S↑ G2/M= S↑ G2/M= S↑ G2/M↓ S = G2/M↑
Cell cycle changes upon CRY2 ectopic expression S↑ G2/M= S↑ G2/M= S↑ G2/M↓ S↑ G2/M=
Cell pre-apoptosis upon treatment with OXA ↑↑↑ ↑↑ ↑↑ ↑↑
Cell pre-apoptosis upon treatment with 5FU ↑↑↑ = ↑↑ ↑↑
Cell apoptosis upon treatment with OXA ↑↑↑ ↑↑ ↑↑ ↑↑
Cell apoptosis upon treatment with 5FU ↑↑↑ = ↑↑ ↑↑
Cell viability upon CRY1 ectopic expression + OXAc ↓ ↓ = ↓
Cell viability upon CRY2 ectopic expression + OXAc ↓ = = ↓
Cell viability upon CRY1 ectopic expression + 5FUc = ↑ ↓ ↑
Cell viability upon CRY2 ectopic expression + 5FUc = ↑ = ↑
acells harvested 21 h after synchronization with serum shock; bcells harvested 22 h after synchronization with serum shock; Ø protein not detected, GOF gain of
function; ccompared to mock transfected cells
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Fig. 4 (See legend on next page.)
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From these studies gender comes out as the single pre-
dictor of survival, conditioning the outcome of chrono-
FLO4 and determining genetic variation of metabolic
responses that influence time-related variables and hinder
administration of maximal effective dosing. A different geno-
typic profile between males and females could characterize
CRC patients and the higher burden of toxicity reported in
women treated with fluorouracil-based chemotherapy may
be also due to the lower expression of dihydropyrimidine de-
hydrogenase (DPD) found in the tumours of female patients
and/or to the gender dependency of circadian pharmacology
[31]. Translational studies of circadian genes that influence
pharmacokinetics, pharmacodynamics, and drug metabolism
may highlight these critical issues and may point out
the molecular biomarkers that could drive optimal tim-
ing of chronochemotherapy delivery schedules.
Patients bearing higher CRY1 and CRY2 expression ex-
hibited a poorer survival in Kaplan-Meier survival curves.
These data corroborate the reported lower overall and dis-
ease free survival rate related to higher CRY1 expression
[32], and are supported by epidemiological data eviden-
cing that CRC related mortality rates are higher in men
than in women [16, 17].
Evaluation of time related pattern of cryptochrome
genes expression in the CaCo2, HCT116, HT29 and
SW480 cell lines after synchronization with serum shock
produced variable results: CRY1 and CRY2 mRNAs chan-
ged in a time related manner in all the cell lines examined
and showed 24-h periodicity of variation only in HCT116
cells. These results might be related to the neoplastic na-
ture of the examined cell lines and might be interpreted
taking into account previous studies that assessed clock
gene expression in the mouse gastrointestinal mucosa
showing circadian rhythmicity only in some studies for
CRY1 and no oscillation for CRY2 [3, 33–35].
Pinpointing cryptochrome gene expression in cells har-
vested 21 h after serum shock induced synchronization,
CaCo2, HCT116 and HT29cells showed higher CRY1 and
CRY2 mRNA levels compared to SW480 cells, whereas
the SW480 cell line showed higher CRY1 levels at several
time points considering not synchronized cells. Our re-
sults are in agreement with a previous report showing
higher CRY1 expression in SW480 cell, disclosing high
proliferation rate and invasiveness [32]. Of note, our
parameters were appraised after cell synchronization to
obtain more valuable and reliable results. Furthermore,
we did not find a direct correlation between CRY1 and
CRY2 mRNA and the corresponding protein levels,
evaluated in cells harvested 22 h after synchronization,
likely due to the gap between gene transcription and
protein synthesis or tagging and degradation processes.
We also carried out FISH experiments to verify whether
the different cryptochrome genes expression in the stud-
ied cell lines could be related to gene copy number varia-
tions. A low copy number gain was detected for CRY1 in
HT29 and CaCo2 cell lines and for CRY2 in SW480 and
HT29 cells, suggesting that copy number gain does not
fully explain the differences in gene expression observed
and that epigenetic mechanisms might likely be involved.
FISH and immunoblotting experiments thus suggest that
cryptochrome gene expression could be post-transcriptionally
and post-translationally regulated in the colon cancer
cell lines examined.
Ectopic expression of CRY1 and CRY2 decreased apop-
tosis/preapoptosis in CaCo2, HT29 and SW480 cells, in-
creased proliferation rate and percentage of cells in S
phase in the four colon cancer cell lines examined, cor-
roborating the evidence of poorer prognosis observed in
CRC patients showing higher expression of cryptochrome
genes in their tumour tissues.
A number of drugs can be employed for CRC chemo-
therapy and frequently, a combination of two or more of
these drugs is more effective. A common drug combin-
ation used for adjuvant treatment include OXA and 5FU,
which is often given with folinic acid, which enhances its
action. The Challenging with OXA and 5FU the examined
colon cancer cell lines evidenced different changes of cyto-
pathic effects in the colon cancer cell lines studied after
each cryptochrome gene transfection. Interestingly,
recent studies evidenced that CRY1 modulates the ATR-
mediated DNA damage checkpoint response by interact-
ing in a time-of-day-dependent manner with TIMELESS,
another protein involved in the molecular clockwork in
addition to the DNA damage response, and CRY2 takes
part in the regulation of DNA damage repair as well as
the maintenance of genomic stability [36, 37].
The genotypic-phenotypic associations and effects on
overall survival of cryptochrome genes reported in our
CRC patients and the different CRY1 and CRY2 expres-
sion levels and time related profiles plus the different
apoptotic, proliferative and cytotoxic responses observed
in vitro in the studied colon cancer cell lines could be
(See figure on previous page.)
Fig. 4 Evaluation of CRY1 and CRY2 protein levels in colon cancer cell lines. a Immunoblot detection of CRY1 and CRY2 protein in CaCo2, HCT116,
HT29 and SW480 cells harvested 22 h after synchronization with serum shock; b-c) Immunoblot detection of CRY1 and CRY2 protein in CaCo2,
HCT116, HT29 and SW480 cells with and without cryptochrome gene ectopic expression. Western blot analysis was performed to detect the protein
expression levels of CRY1 and CRY2 upon transfection using anti-CRY1 and anti-CRY2 antibody as well as anti-FLAG antibody. β-Actin antibody was
used as control. d basal p53 levels in CaCo2, HCT116, HT29 and SW480 cells; e) p53 levels upon CRY1 and CRY2 ectopic expression in the four colon
cancer cell lines; bars, standard deviation (SD); *P < 0.05; **P < 0.01. Each western blot analysis was performed five times
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Fig. 5 FISH experiments performed on colon cancer cell lines. a-b UCSC maps of the BAC clones used for CRY1 (a) and CRY2 (b) copy number
alterations. Genes are reported in blue at the bottom of the figures. c-f FISH results for CRY1 and CRY2 probes (in green and red, respectively)
obtained in HCT116 (c), SW480 (d); HT29 (e), and CACO-2 (f) cells. See text for details
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related to the dissimilarity of their chromosomal abnor-
malities and genetic background. In some way, these
data may suggest a molecular pathophysiological mech-
anism causing the differences in disease behavior and re-
sponse to therapy observed in vivo in CRC patients. In
this respect, a crucial factor could be represented by p53
status. The relationship with p53 status has been pro-
posed as an additional layer of regulation in vivo. Indeed,
analysis of the chosen colon cancer cell lines showed
that higher CRY1 and CRY2 protein levels coincided with
a wild type p53 as in HCT116 cells and that this condition
only marginally affected the apoptotic and cell prolifera-
tion characteristics of the cells upon ectopic expression.
In contrast, lower CRY and CRY2 levels as in HT29 and
SW480 cells were associated with a mutated p53 and a
more robust apoptosis and proliferation upon transfec-
tion. Overall, the phenotypic differences among the colon
cancer cell lines investigated may underlie diverse CRY1
and CRY2 expression patterns and a related genetic land-
scape that could influence cell survival and response to
chemotherapy. The gene coding for p53 (TP53) is ex-
pected to be mutated in 40–50 % of CRCs, and our colon
cancer cell lines carried different TP53 mutations and
showed variable expression of p53 protein [38]. Particu-
larly, CaCo2 cells show a TP53 point mutation determin-
ing undetectable p53 protein by immunohistochemistry,
HCT116 cells do not show TP53 mutation, HT29 and
SW480 cells show TP53 point mutation, p53R273H and
p53R273H/P309S respectively, which induces the mutated
proteins to attain ‘gain of function’ (GOF), dynamically in-
volved in cancer development and progression [39]. The
interplay between cryptochrome genes and p53 has been
extensively studied in mouse models. In Cry1-/-Cry2-/-
mutant mice radiation-induced morbidity and mortality
are similar to that observed in the wild-type controls. In
the same way, the DNA damage checkpoint response to
ionizing radiation of Cry1-/-Cry2-/- mutant fibroblasts is
comparable to that of the wild-type controls, suggesting
that cryptochrome genes and biological clock disruption
for itself is not capable to prejudice mammalian DNA
Fig. 6 Evaluation of apoptosis changes upon CRY1 and CRY2 ectopic transfection in colon cancer cell lines. a-b Apoptosis was evaluated by
AnnexinV-FITC and Propidium Iodide stained cells using Apoptosis Detection Kit (BD Biosciences), according to the manufacturer’s protocols. All
flow cytometry results were analyzed with FACSuite Software v.1.0.5.3841 (BD Biosciences); bars, standard deviation (SD); *P < 0.05; **P < 0.01; three
biological replicates were prepared and each assayed in triplicate and the results expressed as mean ± standard deviation (SD)
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damage checkpoints and repair [40]. On the contrary, the
p53-/-Cry1-/-Cry2-/- mice show delayed spontaneous car-
cinogenesis when compared to p53-/- mice, suggesting that
Cry mutation may activate p53-independent apoptosis path-
ways. Indeed, cell lines generated from the p53-/-Cry1-/-
Cry2-/- mice are more susceptible to UV-induced apoptosis
when challenged with genotoxic stress respect to p53-/- cells
in the presence of preserved DNA damage checkpoint func-
tions and repair [41]. When tumours arising from oncogenic
Ras-transformed p53-/- and p53-/-Cry1-/-Cry2-/- cells
are treated with OXA, p53−/− tumours continue to grow
whereas p53-/-Cry1-/-Cry2-/- tumours exhibit extensive
apoptosis and stop growing, corroborating the evidence
that cryptochrome disruption in p53-/- cells makes them
more sensitive to chemotherapy by OXA [42]. Essen-
tially, cryptochrome gene mutation hampers tumori-
genesis in p53-/- mice by means of: (i) stimulation of
p53-independent apoptosis pathways, (ii) reduction of
Fig. 7 Evaluation of proliferation and cell cycle changes upon CRY1 and CRY2 ectopic expression in colon cancer cell lines. a MTT assays performed on
CaCo2, HCT116, HT29 and SW480 cells transfected with CRY1 or CRY2 constructs. Wells containing transfected cells with reagents alone (Mock) were used
as negative control; b) cell counts performed on CaCo2, HCT116, HT29 and SW480 cells transfected with CRY1 or CRY2 constructs. Wells containing
transfected cells with reagents alone (Mock) were used as negative control; three biological replicates were prepared and each assayed in triplicate; the
results were reported as mean ± standard deviation (SD); c) cell cycle analysis was performed three days after transfection on both attached and floating
cells using the Cell-Cycle Test (BD Biosciences). Propidium Iodide stained cells (>20.000 events) were analyzed on FACSVerse flow cytometer
(BD Biosciences); bars, standard deviation (SD); *P < 0.05; **P < 0.01; four biological replicates were each assayed in triplicate and results were
expressed as mean ± SD
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antiapoptotic action of NF-κB signaling upon inflam-
matory cytokine stimulation, (iii) purging of premalig-
nant and malignant cells with hindrance of overt
tumour formation [43]. In the presence of DNA dam-
age, and with the aim to repair DNA alterations and
prevent accumulation of mutations in the genome of
Fig. 8 Patterns of response to chemotherapeutic agents in colon cancer cell lines. a apoptotic and pre-apoptotic response to treatment with
5-fluorouracil (5-FU) or oxaliplatin (OXA) in CaCo2, HCT116, HT29 and SW480 cells; b) Effect of CRY1 or CRY2 ectopic expression on response to
treatment with 5FU or OXA in colon cancer cell lines. The cell lines were treated with 1 μM, 5 μM and 10 μM of 5FU or OXA for 24 h at 37 °C
in 5 % CO2 atmosphere 48 h after transfection with CRY1 or CRY2 constructs. Wells containing transfected cells with CRY1 or CRY2 constructs
were used as negative control (Mock). Cell viability was determined by MTT assay. bars, standard deviation (SD); *P < 0.05; **P < 0.01; three
biological replicates were each assayed in triplicate and results were expressed as mean ± SD
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daughter cells, normal human cells arrest either in G1
or S phase of the cell cycle. The G1 phase cell cycle ar-
rest relies on p53 and is mainly accomplished by the
cyclin-dependent kinase (Cdk) inhibitor p21(Cip1/Waf1).
The signaling pathway dependent on p53 is modulated
by the circadian protein ARNTL and in particular
ARNTL-silenced cells are not capable to arrest upon
p53 activation due to failure to activate the p53 target
gene p21(Cip1/Waf1). ARNTL is required for the p53-
dependent induction of p21(Cip1/Waf1) and ARNTL sup-
pression affects the ability of p53 to induce cell cycle
arrest upon cellular stress signals such as DNA damage
[44]. ARNTL restrains the G2/M transition by inducing
the expression of WEE kinase that inhibits Cdk1, and
inhibits p21(Cip1/Waf1) expression thus triggering Cdk2
and Cdk1, which prop up the S and M phases; ARNTL
also inhibits c-MYC and thus decreases the expression
of cyclin E and the activity of cyclin E/Cdk2, hindering
the G1/S transition [45]. Interestingly, WEE kinase is
elevated in Cry double-mutant mouse fibroblasts [46],
but their growth rate does not differ from the wild-type
controls, likely through compensation by faster pro-
gression through other cell cycle phases [47]. Based on
these premises, the different phenotypic hallmarks and
patterns of response to chemotherapeutic agents ob-
served in the colon cancer cell lines examined upon
CRY1 and CRY2 ectopic expression must be interpreted
taking into account the interplay between the crypto-
chrome genes and the genetic landscape of the neoplastic
cells. Accordingly, pinpointing two opposite paradigmatic
cell models, we observed increased sensitivity to OXA in
CaCo2 cells, which do not express p53 protein and have
low CRY1, CRY2, ARNTL, c-MYC and WEE expression
levels, whereas no change in sensitivity was shown in
HT29 cells, which are characterized by GOF of mutated
TP53, by low CRY1, CRY2 and ARNTL expression levels,
but high c-MYC and WEE expression levels. Interestingly,
severely decreased effect of 5FU upon ectopic crypto-
chrome gene expression was evidenced in the HCT116
cell line, which is characterized by high endogenous cryp-
tochrome gene expression at mRNA and protein level and
shows increase of p53 levels upon CRY1 and CRY2 ectopic
expression. In view of the translational and clinical impli-
cations, we must consider that cryptochrome and ARNTL
gene expression levels in the tumour tissue of CRC pa-
tients influence chemotherapy response and survival.
CRY2 over-expression in human CRC samples may be
caused by down-regulation of FBXW7, encoding F-box
and WD repeat domain containing 7, E3 ubiquitin protein
ligase, which binds directly to phosphorylated Thr300 of
CRY2 and tags this circadian protein for proteasomal deg-
radation. High CRY2 and low FBXW7 expression in colo-
rectal tumour tissue was correlated with chemoresistance
as well as poorer survival of CRC patients [48]. Besides,
in vitro and in vivo experiments showed that ARNTL
over-expression inhibited colon cancer cell proliferation
and increased CRC sensitivity to OXA. Besides, high
ARNTL expression level in primary tumour specimens
of CRC patients treated with OXA based regimens
(FOLFOX or XELOX) was associated with significantly
longer overall and progression-free survival respect to
patients with low ARNTL levels. The molecular mechan-
ism is related to ARNTL control of G2/M arrest through
ATM pathway activation [49].
Conclusions
In conclusion, in malignant colorectal neoplastic disease
the expression of cryptochrome genes is severely altered,
particularly in elderly subjects, female patients and can-
cers located in the transverse colon. On the other side,
lower expression levels in tumour tissue seem to predict
better survival in CRC patients. The different CRY1 and
CRY2 expression levels and time related profiles plus the
different apoptotic, proliferative and cytotoxic responses
observed in vitro in the studied colon cancer cell lines
could be related to the dissimilarity in their chromosomal
abnormalities and genetic background. The interplay
between cryptochrome genes and different genomic land-
scapes may influence cancer cell phenotype, impinging on
neoplastic disease behavior and response to therapy,
possibly modifying sex dimorphism-related differences
in drug toxicity and outcome measures.
Additional files
Additional file 1: Figure S1. Expression of CRY1 and CRY2 mRNA levels
in colorectal cancer tissue of 461 patients from the TGCA cohort (https://
tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). A box plot is shown
representing the interquartile range (IQR) with median, 25th and 75th
percentile, minimum and maximum values, as well as each outlier
indicated by dots and stars. (JPG 247 kb)
Additional file 2: Figure S2. x-y plots representing the time related mRNA
expression profiles of CRY1 in CaCo2, HCT116, HT29 and SW480 cells with and
without synchronization with serum shock and normalized to non-tumorous
colorectal mucosa. Two biological replicates were each assayed in triplicate
and results were expressed as mean ± standard deviation (SD). (JPG 652 kb)
Additional file 3: Figure S3. x-y plots representing the time related
mRNA expression profiles of CRY1 in CaCo2, HCT116, HT29 and SW480
cells with and without synchronization with serum shock and normalized
to non-tumorous colorectal mucosa. Two biological replicates were each
assayed in triplicate and results were expressed as mean ± standard deviation
(SD). (JPG 568 kb)
Additional file 4: Figure S4. A) x-y plots representing the time related
mRNA expression profiles of ARNTL, WEE and c-MYC in CaCo2, HCT116, HT29
and SW480 cells synchronized after serum shock and harvested at the
indicate time points. Two biological replicates were each assayed in triplicate
and results were expressed as mean ± standard deviation (SD). B) ARNTL,
WEE and c-MYC protein level evaluated by western blotting in a panel of
matched specimens of tumour tissue and non-tumorous tissue. (JPG 473 kb)
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